August 27th 2025
NRX-100, a preservative-free ketamine, announces expanded access policy for treatment of suicidal ideation in depression, offering new hope for patients.
Childhood Trauma and Outcomes With Lithium or Quetiapine in Outpatients With Bipolar Disorder
December 8th 2022Does childhood trauma affect outcomes in bipolar disorder? Researchers analyzed the impact of childhood trauma on outcomes in outpatients with bipolar disorder treated with lithium or quetiapine in a randomized clinical trial.
Read More
Phase 3 Trial of Dexmedetomidine for Bipolar I or II, Schizophrenia Doses First Participants
November 30th 2022The phase 3 SERENITY III trial investigating at-home use of dexmedetomidine (BXCL501) sublingual film for agitation associated with bipolar I or II disorder or schizophrenia has started.
Read More